Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB
NCT03069534
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
500
Enrollment
OTHER
Sponsor class
Conditions
MDR TB
Interventions
DRUG:
RhIL-2
Sponsor
The First Affiliated Hospital with Nanjing Medical University